(CercleFinance.com) – AB Science announces that the European Patent Office has issued a notice of acceptance for a patent relating to methods (i.e. a patent for medical use) for the treatment of mastocytosis severe systemic with its main molecule, masitinib.
This new European patent protects intellectual property
masitinib in this indication until October 2036.
Specifically, masitinib is intended for the treatment of patients with severely symptomatic systemic mastocytosis, including subvariants of indolent and smouldering systemic mastocytosis, who do not respond to optimal symptomatic treatment.
The notice of acceptance (NOA) means that the European Patent Office intends to grant the patent application, EP3359195A1, after the completion of certain steps of the formal procedure.
‘This is good news because it proves once again that the masitinib platform is protected for a period ranging from 12 to 17 years depending on the indication, which allows sufficient time to conduct
to successfully complete the program through registration and to maximize revenue during the commercialization phase,’ said Alain Moussy, CEO of AB Science.
Masitinib has already been granted orphan drug status in mastocytosis by the FDA and EMA.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
